EUVIMEDOpdag EUVIMED
Multizentrische StudieOpen access · CC BY-NC 3.0

Limited Benefit of Additional Chartis® Assessments for Collateral Ventilation Evaluation in Patients with Software Quantified Intact Target Lobe Fissure – Results from a Retrospective Analysis of the German Lung Emphysema Registry

Jacopo Saccomanno iD, Thomas Sgarbossa, Konrad Neumann iD, Franz Stanzel, Stefan Andreas, Stephan Eisenmann iD, Bernd Schmidt, Wolfgang Gesierich, Martin Witzenrath, Ralf Harto Hübner, Lung Emphysema study group

International Journal of Chronic Obstructive Pulmonary Disease · 2025

DOI: 10.2147/copd.s538587 ↗

At a glance

Multizentrische Studie in International Journal of Chronic Obstructive Pulmonary Disease, 2025. Written by Jacopo Saccomanno and 10 co-authors. Institution: Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universitä…. Major MEDLINE topics: Pulmonary Emphysema, Lung, Pneumonectomy, Bronchoscopy. Cited 1 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 3.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Endoscopic lung volume reduction (ELVR) with valves is a treatment option for selected patients with emphysema. Collateral Ventilation (CV) is measured directly with the Chartis® bronchoscopic assessment system (PulmonX Inc. Redwood City, CA, USA) and indirectly via fissure completeness score (FCS) on computed-tomography (CT). It remains unclear, whether the additional Chartis® assessment improves treatment outcome when the target lobe shows intact fissure (FCS ≥95%). Study Design and Methods: This retrospective analysis used data from the German Lungenemphysemregister e.V. a prospective multicenter trial on lung volume reduction therapy. Patients with an intact fissure (FCS ≥95%) of the target lobe undergoing ELVR were included. Treatment outcomes were compared between patients who had a Chartis® measurement prior to ELVR and those who did not.

Results

A total of 262 patients were analyzed: 175 with Chartis® and 87 without. Baseline parameters were comparable between groups. At 3-month follow-up significant improvements in lung function parameters (FEV1, RV, DLCO, pCO2), exercise capacity (6-MWT) and quality of life parameters (SGRQ, mMRC and CAT) were seen in both groups. Treatment efficacy at 3-month follow-up was comparable in patients regardless of previous Chartis® measurements. Furthermore, there was no difference in treatment outcome, when comparing improvements for the right and left lung separately. Responder rates were similar between the groups, with a comparable MCID in both. Complication rates were also largely comparable, except for a higher pneumothorax rate in the no-Chartis group (7% vs 22%).

Discussion

This analysis did not find evidence that a Chartis® assessment provided additional benefit to the treatment response after ELVR at 3-month follow-up in patients with an intact fissure of the target lobe with an FCS ≥95%. These findings may be clinically relevant as they suggest that additional invasive Chartis® measurement might be dispensable in this subgroup.

Subjects

MeSH terms (MEDLINE)

Pulmonary EmphysemaLungPneumonectomyBronchoscopyPulmonary VentilationTomography, X-Ray ComputedSoftwareHumansRetrospective StudiesMaleFemaleGermanyTreatment OutcomeAgedMiddle AgedRegistriesPredictive Value of TestsTime FactorsExercise ToleranceRecovery of FunctionQuality of Life

Author keywords

COPDLung emphysemacollateral ventilationendoscopic lung volume reduction with valves

Authors and institutions

  • Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
  • Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Respiratory Medicine, Lungenklinik Hemer, Hemer, Germany.
  • Zentrum für Pneumologie, Lungenfachklinik Immenhausen, Immenhausen, Germany.
  • German Center for Lung Research (DZL), Berlin, Germany.
  • Department of Respiratory Medicine, Universitätsklinikum Halle, Halle, Germany.

ORCID profiles: Jacopo Saccomanno, Konrad Neumann, Stephan Eisenmann

Cite

APA

Saccomanno, J., Sgarbossa, T., Neumann, K., Stanzel, F., Andreas, S., Eisenmann, S., Schmidt, B., Gesierich, W., Witzenrath, M., Hübner, R. H., & Lung Emphysema study group (2025). Limited Benefit of Additional Chartis® Assessments for Collateral Ventilation Evaluation in Patients with Software Quantified Intact Target Lobe Fissure – Results from a Retrospective Analysis of the German Lung Emphysema Registry. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s538587

Vancouver

Saccomanno J, Sgarbossa T, Neumann K, Stanzel F, Andreas S, Eisenmann S, et al. Limited Benefit of Additional Chartis® Assessments for Collateral Ventilation Evaluation in Patients with Software Quantified Intact Target Lobe Fissure – Results from a Retrospective Analysis of the German Lung Emphysema Registry. International Journal of Chronic Obstructive Pulmonary Disease. 2025. doi:10.2147/copd.s538587

BibTeX
@article{Saccomanno2025,
  author = {Saccomanno, Jacopo and Sgarbossa, Thomas and Neumann, Konrad and Stanzel, Franz and Andreas, Stefan and Eisenmann, Stephan and Schmidt, Bernd and Gesierich, Wolfgang and Witzenrath, Martin and Hübner, Ralf Harto and Lung Emphysema study group, Lung Emphysema study group},
  title = {Limited Benefit of Additional Chartis® Assessments for Collateral Ventilation Evaluation in Patients with Software Quantified Intact Target Lobe Fissure – Results from a Retrospective Analysis of the German Lung Emphysema Registry},
  journal = {International Journal of Chronic Obstructive Pulmonary Disease},
  year = {2025},
  doi = {10.2147/copd.s538587}
}
Start for free →